Namely, revenue from sales of key 14 drugs grew to 356.6 billion yen in Q2 2021, which is 23.9% more than in Q2 2020 and 6.3% more than in Q1 2021. Source: Author's elaboration, based on quarterly securities reports Nevertheless, the company's management strategy to develop the key 5 therapeutic areas is paying off, namely, the revenue of the main 14 drugs continues to grow from quarter to quarter in most regions of the world, In addition, the company sold five non-core medicines, mainly the prescription gastroenterology assets to Adium Pharma SA. The decrease in revenues in Q2 2021 versus Q1 2021 is primarily due to the sale of some of its assets in 2021, namely, Takeda completed the sale of four Teijin Pharma diabetes products in the first half of 2021. Source: Author's elaboration, based on Seeking Alpha Under the leadership of Christophe Weber, the company has remained stable in revenue, generating approximately $7.6 billion per quarter. Revenue Growth Opportunitiesĭespite the continued difficult situation caused by the delta and omicron variants of COVID-19 in the second half of 2021, which still affects the financial position of many companies in the pharmaceutical industry, including Takeda, the company's business continues to develop in a positive direction. With a 5.7% dividend yield, revenue growth year on year, a significant 27.5% drop in net debt over the last year and a potential expansion of the company's portfolio in the next 3 years, Takeda Pharmaceutical is an excellent candidate for long-term investors. In the next few years, the company's management plans to obtain approval for more than 10 drugs, which will help to continue to grow Takeda's net profit. In addition, the improvement in the company's financial position has enabled the start of the 100 billion yen buyback of Takeda shares starting in 2021.
Thanks to the efficient work of the company's management, Takeda's net debt was about $32.6 billion in Q2 2021, which is 27.5% less than a year earlier and 3.6% less than in Q1 2021. In addition, sales of another drug, TAKECAB, were 24.8 billion yen in Q2 2021, up 2.1% Q1 2021 and 25.9% Q2 2020. ENTYVIO's global sales totaled around ¥130.5 billion in Q2 2021, up 4.1% quarter-on-quarter and 23.5% Q1 2020.
The company has several medicines in its portfolio, each of which brings the company more than 1 billion in revenue per year. Revenue for the company's core 14 medicines increased 23.9% in 2Q2021 versus 1Q2021, while operating income exceeded expectations, increasing 33.6% over the past 12 months versus 2020.
Takeda Pharmaceutical ( NYSE: TAK) is one of the largest pharmaceutical companies not only in Asia, but also worldwide, producing medicines used to treat cancer, neurological, gastroenterological diseases and, as a result, can improve the quality of life of millions of patients around the world.
0 kommentar(er)
